Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FURIN | P09958 | 10/20 | 0.41 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | MAP1LC3B | Q9GZQ8 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.34 |
| ▸ | NPY1R | P25929 | 1/20 | 0.34 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22690514 | 1.00 | FURIN (0.41) | FURINC3AR1HTTMAP1LC3BSMN1; SMN2 | |
| SCHEMBL29528370 | 0.94 | FURIN (0.40) | FURINHTTMAP1LC3BSMN1; SMN2NPY1R | |
| SCHEMBL28592858 | 0.94 | FURIN (0.41) | FURINC3AR1HTTMAP1LC3BSMN1; SMN2 | |
| SCHEMBL29623561 | 0.94 | FURIN (0.40) | FURINHTTMAP1LC3BSMN1; SMN2NPY1R | |
| SCHEMBL28592862 | 0.94 | FURIN (0.41) | FURINC3AR1HTTMAP1LC3BSMN1; SMN2 | |
| SCHEMBL17637465 | 0.93 | FURIN (0.41) | FURINC3AR1HTTMAP1LC3BSMN1; SMN2 | |
| SCHEMBL22690491 | 0.93 | FURIN (0.41) | FURINC3AR1HTTMAP1LC3BSMN1; SMN2 | |
| SCHEMBL30483106 | 0.93 | FURIN (0.40) | FURINHTTMAP1LC3BSMN1; SMN2KLKB1 | |
| SCHEMBL22618772 | 0.93 | FURIN (0.40) | FURINC3AR1HTTNPY1RROCK2 | |
| SCHEMBL28604515 | 0.92 | FURIN (0.41) | FURINC3AR1NPY1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3972649-B1 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | NOVARTIS AG (CH) | 2026-05-13 | — | — | EP | disclosed |
| US-20240042051-A1 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | LES LABORATOIRES SERVIER (FR) | 2024-02-08 | — | — | US | disclosed |
| EP-4251208-A1 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | Novartis AG (CH) | 2023-10-04 | — | — | EP | disclosed |
| US-20230092679-A1 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2023-03-23 | — | — | US | disclosed |
| US-20230081720-A1 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2023-03-16 | — | — | US | disclosed |
| WO-2022115451-A1 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | NOVARTIS AG (CH) | 2022-06-02 | — | — | WO | disclosed |
| EP-3972651-A2 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | Novartis AG (CH) | 2022-03-30 | — | — | EP | disclosed |
| US-11202837-B2 | Biological materials and uses thereof | ANTIKOR BIOPHARMA LIMITED (GB) | 2021-12-21 | — | — | US | disclosed |
| WO-2020236817-A2 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | NOVARTIS AG (CH) | 2020-11-26 | — | — | WO | disclosed |
| WO-2020236825-A2 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | NOVARTIS AG (CH) | 2020-11-26 | — | — | WO | disclosed |
| US-20170360951-A1 | BIOLOGICAL MATERIALS AND USES THEREOF | ANTIKOR BIOPHARMA LIMITED (GB) | 2017-12-21 | — | — | US | disclosed |
| WO-2016046574-A1 | BIOLOGICAL MATERIALS AND USES THEREOF | ANTIKOR BIOPHARMA LIMITED (GB) | 2016-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11202837-B2 | Biological materials and uses thereof | CD47, LNPEP, TIE1 | FURIN 102/4885C3AR1 40/4885HTT 1929/4885 |
| US-20230092679-A1 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | MCL1, BCL9, BAK1 | FURIN 3583/4885C3AR1 3376/4885HTT 2963/4885 |
| US-20230081720-A1 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | MCL1, CD74, CD99 | FURIN 3922/4885C3AR1 4036/4885HTT 3594/4885 |
| US-20240042051-A1 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | MCL1, CD58, LENG8 | FURIN 2649/4885C3AR1 2912/4885HTT 3986/4885 |
| US-20170360951-A1 | BIOLOGICAL MATERIALS AND USES THEREOF | CD47, LNPEP, TIE1 | FURIN 102/4885C3AR1 40/4885HTT 1929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.